在糖尿病中阿迪波涅丁的心脏保护作用
Tara Kazemi1, Yuanjie Mao2,3, Tina Zhang4
1Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 45701, USA.
Current diabetes reports
|October 13, 2025
概括
阿迪波涅丁在糖尿病中提供心血管保护,但高水平矛盾地增加了死亡风险. 需要进一步的研究,以了解其在糖尿病心力衰竭中针对性治疗的双重作用.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 代谢健康 代谢健康
背景情况:
- 脂肪细胞分泌的激素阿迪波内克丁 (Adiponectin) 对新陈代谢平衡和心血管健康至关重要.
- 它表现出保护作用,如提高胰岛素敏感性和减少炎症.
- "皮菌素悖论"强调了高皮菌素水平和心血管死亡率增加之间的复杂关联.
研究的目的:
- 审查阿迪波涅丁在1型和2型糖尿病中的心脏保护作用.
- 探索其在调节葡萄糖代谢和预防心血管并发症方面的作用.
- 分析其对糖尿病心肌病和充血性心力衰竭的影响.
主要方法:
- 对adiponectin关键研究的系统审查.
- 在糖尿病亚型中对阿迪波内克的作用进行比较分析.
- 专注于心血管结果,特别是在糖尿病心肌病和心力衰竭中.
主要成果:
- 在糖尿病人群中,阿迪波涅丁在心血管健康方面发挥了多方面的作用.
- 它对心血管结果的影响因糖尿病亚型而异,特别是在糖尿病心肌病症中.
- "阿迪波内克丁悖论"使临床解释变得复杂,需要进一步调查.
结论:
- 了解阿迪波涅丁的双重性质对于管理糖尿病心血管风险至关重要.
- 调节阿迪波涅克水平的治疗策略需要进一步研究,特别是对于糖尿病和心力衰竭患者.
- 有针对性的干预措施对于改善糖尿病患者心血管状况至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
Coronary Artery Disease I: Introduction
878
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
cAMP-dependent Protein Kinase Pathways
8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
Heart Failure Drugs: β-Blockers
770
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
770


